Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite. 2007

Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
The Laboratory of Cardiac Surgery Department of Cardiac Surgery, University of Heidelberg, 69120 Heidelberg, Germany. radovitstamas@yahoo.com

Reactive oxygen species, such as myeloperoxidase-derived hypochlorite, induce oxidative stress and DNA injury. The subsequent activation of the DNA-damage-poly(ADP-ribose) polymerase (PARP) pathway has been implicated in the pathogenesis of various diseases, including ischemia-reperfusion injury, circulatory shock, diabetic complications, and atherosclerosis. We investigated the effect of PARP inhibition on the impaired endothelium-dependent vasorelaxation induced by hypochlorite. In organ bath experiments for isometric tension, we investigated the endothelium-dependent and endothelium-independent vasorelaxation of isolated rat aortic rings using cumulative concentrations of acetylcholine and sodium nitro-prusside. Endothelial dysfunction was induced by exposing rings to hypochlorite (100-400 microM). In the treatment group, rings were preincubated with the PARP inhibitor INO-1001. DNA strand breaks were assessed by the TUNEL method. Immunohistochemistry was performed for 4-hydroxynonenal (a marker of lipid peroxidation), nitrotyrosine (a marker of nitrosative stress), and poly(ADP-ribose) (an enzymatic product of PARP). Exposure to hypochlorite resulted in a dose-dependent impairment of endothelium-dependent vasorelaxation of aortic rings, which was significantly improved by PARP inhibition, whereas the endothelium-independent vasorelaxation remained unaffected. In the hypochlorite groups we found increased DNA breakage, lipidperoxidation, and enhanced nitrotyrosine formation. The hypochloride-induced activation of PARP was prevented by INO-1001. Our results demonstrate that PARP activation contributes to the pathogenesis of hypochlorite-induced endothelial dysfunction, which can be prevented by PARP inhibitors.

UI MeSH Term Description Entries
D006997 Hypochlorous Acid An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent. Hypochlorite,Hypochlorous Acids
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D011065 Poly(ADP-ribose) Polymerases Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE. ADP-Ribosyltransferase (Polymerizing),Poly ADP Ribose Polymerase,Poly(ADP-Ribose) Synthase,Poly(ADP-ribose) Polymerase,PARP Polymerase,Poly ADP Ribose Transferase,Poly ADP-Ribose Synthase,Poly(ADP-Ribose) Transferase,Poly(ADPR) Polymerase,Poly(ADPribose) Polymerase,Poly ADP Ribose Synthase,Polymerase, PARP,Synthase, Poly ADP-Ribose
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000067856 Poly(ADP-ribose) Polymerase Inhibitors Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. Inhibitors of Poly(ADP-ribose) Polymerase,PARP Inhibitor,Poly(ADP-Ribose) Polymerase Inhibitor,Poly(ADP-ribosylation) Inhibitor,Inhibitors of Poly(ADP-ribose) Polymerases,PARP Inhibitors,Poly(ADP-ribosylation) Inhibitors,Inhibitor, PARP,Inhibitors, PARP
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
April 2009, Cardiovascular drugs and therapy,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
August 2014, Upsala journal of medical sciences,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
October 2009, Biochemical pharmacology,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
December 2015, Clinical and experimental pharmacology & physiology,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
October 2004, Pharmacology,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
November 2011, Biochemical and biophysical research communications,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
October 2001, Circulation research,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
September 2005, The Annals of thoracic surgery,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
June 1997, Mutation research,
Tamás Radovits, and Julia Zotkina, and Li-Ni Lin, and Timo Bömicke, and Rawa Arif, and Domokos Gerö, and Eszter M Horváth, and Matthias Karck, and Csaba Szabó, and Gábor Szabó
June 2023, Pulmonary pharmacology & therapeutics,
Copied contents to your clipboard!